Development Of a Concentrated Tranexamic Acid (TXA) Intramuscular Injection
This federal contract opportunity has been awarded to on September 30, 2025.
Award Information
HEALTH AND HUMAN SERVICES, DEPARTMENT OF awarded this contract to for $186,004,780 on September 30, 2025, as part of federal procurement initiatives.
This award is part of federal acquisition procurement activities.
- Award Number
- 75A50125C00018
- Award Amount
- $186,004,780
- Award Date
- September 30, 2025
Key Takeaways
- No response deadline specified - contact the agency for details
- Full and open competition - all businesses eligible to bid
- Work to be performed in WASHINGTON, DC
- Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Contract Details
- Notice ID
- 75A50125C00018
- Opportunity Type
- Award Notice
- Sub-Agency
- OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
- Office
- BARDA - ASPR / DAAPPO / BARDA DCMA
- Posted Date
- Wednesday, October 1, 2025
- Response Deadline
- Not specified
- PSC Code
- AN13
- Set-Aside
- Full & Open Competition
- Place of Performance
- WASHINGTON, DC, 20515
- Status
- Active
Description
This award is for the development of a concentrated Tranexamic Acid (TXA) Intramuscular Injection. The Government seeks this development in order to receive FDA approval for the concentrated IM TXA formulation that can be delivered in a pref-filled syringe or a dedicated autoinjector. This contract action was awarded competitively as a Cost Share Contract. A Cost Share Contract was used in accordance with FAR 35.006 (c) due to an absence of precise specifications and difficulties in estimating costs with accuracy.
Why This Opportunity Matters
HEALTH AND HUMAN SERVICES, DEPARTMENT OF is seeking responses for research and development in biotechnology (except nanobiotechnology) in WASHINGTON, DC.
Similar Opportunities
Browse Related
Looking for more opportunities?
Browse our full directory of government contracts
